Rapid detection of spermine for prostate cancer screening based on lateral flow immunoassay

WO2024194691A3PCT designated stage expired Publication Date: 2024-11-07NEW LIFE MEDICINE TECH CO LTD
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
PCT/IB2024/000149
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-03-21
Filing Date
2024-03-21
Publication Date
2024-11-07

AI Technical Summary

Technical Problem

Current diagnostic methods for prostate cancer are invasive and often cause discomfort to patients, and existing sensors for detecting spermine, a biomarker for prostate cancer, require advanced instruments or electricity, limiting their use for point-of-care applications.

Method used

A lateral flow immunoassay (LFIA) test device comprising a sample pad, a conjugate pad with spermine-detection antibody conjugate, and a membrane with a test and control region, using citrate-capped gold nanoparticles and specific linkers for selective spermine detection, allowing for rapid and portable spermine detection in liquid samples.

Benefits of technology

The LFIA device enables rapid, low-cost, and portable detection of spermine in urine samples, providing a visual signal indicative of prostate cancer presence, facilitating early detection and reducing patient discomfort.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IB2024000149_07112024_PF_FP_ABST
    Figure IB2024000149_07112024_PF_FP_ABST
Patent Text Reader

Abstract

A test device for detecting spermine in a liquid sample and methods of use thereof, wherein the test device includes, in sequential order: a sample pad, a conjugate pad, a membrane, and an absorbent pad, wherein: the conjugate pad comprises a sperminedetection antibody conjugate comprising a gold nanoparticle conjugated to one more spermine detection antibodies via one or more first linkers, wherein the one or more spermine detection antibodies selectively bind to spermine and the spermine-detection antibody conjugate is mobilizable; the membrane includes, in sequential order from the conjugate pad: a test region and a control region, wherein the test region includes a spermine carrier protein conjugate comprising spermine conjugated via a second linker to a carrier protein and the control region includes a secondary antibody, wherein the secondary antibody is immobilized on the membrane and the secondary antibody binds to the spermine detection antibody.
Need to check novelty before this filing date? Find Prior Art

Description

RAPID DETECTION OF SPERMINE FOR PROSTATE CANCERSCREENING BASED ON LATERAL FLOW IMMUNOASSAYCROSS-REFERENCE TO RELATED APPLICATIONS[1] The present application claims priority from U.S. Provisional Patent Application No. 63 / 453,491, filed on March 21, 2023, which is hereby incorporated by reference in its entirety.BACKGROUND[2] The increasing PC rate has drawn substantial attention and it ranks the second common cancer in men.1The number is expected to grow because of population aging and economic growth.2Although PC is a slow-spreading type cancer, it shows no symptoms at the early stage. The current diagnostic methods for PC are mostly invasive. The digital rectal examination is a simple test that involves the insertion of gloved finger by the doctor. The rectum of the patient is inspected by feeling abnormal lumps or enlargements.3, 4Biopsy has also been recognized as a reliable method for PC diagnosis.5, 6The doctor inserts a needle probe into the prostate and collect tissues for microscopic examination. Alternatively, the prostate antigen (PSA) test7is developed as a less invasive PC diagnosis. The PSA level in the blood is used as a reference to access the risk of PC. Although the above testing methods are widely used by doctors, they cause possible wounds, bleeding and pain to the patients.[3] Recent research suggested the use of small molecules as biomarkers for cancer diagnosis.8 13. Among them, Spm is one of the important biomarkers in the biogenic amine family. It has also been shown to be useful for the detection of PC. A fluorescence sensor based on graphene quantum dot and organic dye had been developed for Spm detection.14The sensor was able to detect Spm at sub-micromolar level in human urine sample. In another report, the quenching of pepsin-functionalized gold nanoclustersacted as a reporting signal for Spm detection.15In addition to optical sensing, Spm could also be detected by electrochemical approach. The recent work on the impedomatic sensing of Spm using plastic electrode presented the feasibility of point-of-care (POC) sensing for PC.16The selectivity of Spm was attributed to the boronic acid on the electrode. Despite the effort, the developed sensors either required advanced instruments for readout or electricity for powering. Therefore, it is vital to develop low cost, portable and simple sensors for POC testing applications.[4] LFIA was used as a POC device for the rapid screening of patients in the COVID- 19 outbreak in the sandwich format.17 19The test provided simple readout using the casted lines on the nitrocellulose membrane (NCM) within tens of minute. The selectivity of LFIA is attributed to the conjugation of species-specific antibody on the nanoprobe. AuNPs were used for readout because they present strong optical absorption due to their plasmonic absorption property, this enable them to be a promising candidate for colorimetric detection.20-22[5] There thus exists a need for a testing device useful for detecting spermine in a liquid sample.SUMMARY[6] Provided herein is a test device for detecting spermine in a liquid sample, the test device comprising, in sequential order: a sample pad, a conjugate pad, a membrane, and an absorbent pad, wherein: the conjugate pad comprises a spermine-detection antibody conjugate comprising a gold nanoparticle conjugated to one more spermine detection antibodies via one or more first linkers, wherein the one or more spermine detection antibodies selectively bind to spermine and the spermine-detection antibody conjugate is mobilizable; the membrane comprises, in sequential order from the conjugate pad: a test region and a control region, wherein the test region comprises a spermine carrierprotein conjugate comprising spermine conjugated via a second linker to a carrier protein and the control region comprises a secondary antibody, wherein the secondary antibody is immobilized on the membrane and the secondary antibody binds to the spermine detection antibody.[7] In certain embodiments, the gold nanoparticle is a citrate capped gold nanoparticle.[8] In certain embodiments, each of the one or more first linkers has a formula: *- S(CH2)m(C=0)NH**-, wherein m is 1-16, * represents a surface of the gold nanoparticle, and N** represents a nitrogen present in the one or more sperminedetection antibodies.[9] In certain embodiments, m is 6-12.

[0010] In certain embodiments, the carrier protein comprises bovine serum albumin, human serum albumin, keyhole limpet hemocyanin, Concholepas concholepas hemocyanin or immunoglobulin Fc domain.

[0011] In certain embodiments, the secondary antibody is an immunoglobulin G (IgG) antibody.

[0012] In certain embodiments, the sample pad further comprises bovine serum albumin and a non-ionic surfactant and the conjugate pad further comprises a non-ionic surfactant.

[0013] In certain embodiments, the second linker is -(N =CH)(CHT)„(CH=N )-, wherein n is a whole number selected from 2-6: N+represents a nitrogen present in the spermine and Ntrepresents a nitrogen present in the carrier protein.

[0014] In certain embodiments, the gold nanoparticle is a citrate capped gold nanoparticle, the carrier protein is bovine serum albumin, the second linker is - (Nt=CH)(CH2)n(CH=Nt)-, wherein n is a whole number selected from 2-5; N* representsa nitrogen present in the spermine and N#represents a nitrogen present in the carrier protein, each of the one or more first linkers has a formula: *-S(CH2)m(C=0)NH**-, wherein m is 8-12, * represents a surface of the gold nanoparticle, and N** represents a nitrogen present in each of the one or more spermine-detection antibodies.

[0015] In certain embodiments, the test region is prepared by depositing a solution comprising the spermine-carrier protein at a concentration of 0.5-1.0 mg / mL.

[0016] In certain embodiments, the control region is prepared by depositing a solution comprising an immunoglobulin G (IgG) antibody at a concentration of at least 0.05 mg / mL.

[0017] In certain embodiments, the test region is prepared by depositing a solution comprising the spermine-carrier protein at a concentration of 0.5- 1.0 mg / mL; and the control region is prepared by depositing a solution comprising an immunoglobulin G (IgG) antibody at a concentration of at least 0.05 mg / mL.

[0018] In certain embodiments, m is 10 and n is 3.

[0019] In a second aspect, provided herein is a method of detecting spermine in a liquid sample, the method comprising: providing the test device described herein; applying the liquid sample on the sample pad resulting in flow of the liquid sample from the sample pad through the conjugate pad and the membrane to the absorbent pad; detecting a presence or an absence of a visual signal at the test region; and optionally detecting a presence or an absence of a visual signal at the control region, wherein the detection of the presence or the absence of the visual signal at the test region is indicative of spermine in the liquid sample.

[0020] In certain embodiments, the detection of the presence or the absence of the visual signal at the test region is indicative of spermine above a threshold concentration in the liquid sample.

[0021] In certain embodiments, the liquid sample comprises a urine sample obtained from a subject.

[0022] In certain embodiments, the liquid sample further comprises phosphate buffered saline.

[0023] In certain embodiments, the liquid sample further comprises bovine serum albumin and a non-ionic surfactant.

[0024] In certain embodiments, the sample pad further comprises bovine serum albumin and a non-ionic surfactant and the conjugate pad further comprises a non-ionic surfactant.

[0025] In certain embodiments, the liquid sample comprises a urine sample obtained from a human subject and the method further comprises determining based on whether the sample contains spermine above the threshold concentration that the human subject suffers from prostate cancer.BRIEF DESCRIPTION OF THE DRAWINGS

[0026] The foregoing aspects and many of the attendant advantages of this invention will become more readily appreciated and understood by reference to the following detailed description, when taken in conjunction with the accompanying drawings.

[0027] Figure 1 Schematic diagram of the LFIA device for Spm detection

[0028] Figure 2 (a) TEM image of the as-synthesized Cit-AuNPs (Scale bar of inset is 10 nm), (b) UV-vis absorption of Cit-AuNPs and MUA-AuNPs, (c) DLS sizes of AuNPs at each modification stage and (d) Gel electrophoresis of AuNPs.

[0029] Figure 3 Optimization of BSA-Spm concentration at 0.125, 0.25, 0.5, 0.75 and 1 mg / mL.

[0030] Figure 4 Detection of spiked Spm in running buffer (RB) at 2, 1, 0.2, 0.1 and 0.02 ppm.

[0031] Figure 5 Specificity test of LFIA using PUT and 1 ,6-diaminohexane as disturbance, both targets were of 0.2 ppm.

[0032] Figure 6 shows test results from optimization of anti-rabbit IgG antibody concentration at 0.05, 0.125, 0.25, and 0.5 mg / mL at the control region.

[0033] Figure 7 shows LFIA results using 48 clinical urine samples. * indicates PCa urine sample.DETAILED DESCRIPTION

[0034] Definitions

[0035] Throughout the present disclosure, unless the context requires otherwise, the word "comprise" or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated integer or group of integers but not the exclusion of any other integer or group of integers. It is also noted that in this disclosure and particularly in the claims and / or paragraphs, terms such as “comprises”, “comprised”, “comprising” and the like can have the meaning attributed to it in U.S. Patent law; e.g., they can mean “includes”, “included”, “including”, and the like; and that terms such as “consisting essentially of’ and “consists essentially of’ have the meaning ascribed to them in U.S. Patent law, e.g., they allow for elements not explicitly recited, but exclude elements that are found in the prior art or that affect a basic or novel characteristic of the present invention.

[0036] Furthermore, throughout the present disclosure and claims, unless the context requires otherwise, the word “include” or variations such as “includes” or “including”,will be understood to imply the inclusion of a stated integer or group of integers, but not the exclusion of any other integer or group of integers.

[0037] The use of the singular herein includes the plural (and vice versa) unless specifically stated otherwise. In addition, where the use of the term "about" is before a quantitative value, the present teachings also include the specific quantitative value itself, unless specifically stated otherwise. As used herein, the term "about" refers to a ±10%, ±7%, ±5%, ±3%, ±1%, or ±0% variation from the nominal value unless otherwise indicated or inferred.

[0038] As used herein, the term “antibody’" encompasses antibodies and antibody fragments thereof, derived from any antibody-producing mammal (e.g., mouse, rat, rabbit, and primate including human), that specifically bind to an antigen of interest. Exemplary antibodies include polyclonal, monoclonal and recombinant antibodies; multi-specific antibodies (e.g., bispecific antibodies); humanized antibodies; murine antibodies; chimeric, mouse-human, mouse-primate, primate-human monoclonal antibodies; and anti-idiotype antibodies. The antigen-binding molecule can be any intact antibody molecule or fragment thereof (e.g., with a functional antigen-binding domain).

[0039] An antibody fragment is a portion derived from or related to a full-length antibody, preferably including the complementarity-determining regions (CDRs), antigen binding regions, or variable regions thereof. Illustrative examples of antibody fragments useful in the present disclosure include Fab, Fab', F(ab)2, F(ab')2 and Fv fragments, scFv fragments, diabodies, linear antibodies, single-chain antibody molecules, multispecific antibodies formed from antibody fragments, and the like. A “single-chain Fv” or “scFv” antibody fragment comprises the VH and VL domains of an antibody, wherein these domains are present in a single polypeptide chain. The Fvpolypeptide can further comprise a polypeptide linker between the VH and VL domains, which enables the scFv to form the desired structure for antigen binding. Antibody fragments can be produced recombinantly, or through enzymatic digestion.

[0040] Provided herein is a test device for detecting spermine in a liquid sample, the test device comprising, in sequential order: a sample pad, a conjugate pad, a membrane, and an absorbent pad, wherein: the conjugate pad comprises a spermine-detection antibody conjugate comprising a gold nanoparticle conjugated to one more spermine detection antibodies via one or more first linkers, wherein the one or more spermine detection antibodies selectively bind to spermine and the spermine-detection antibody conjugate is mobilizable; the membrane comprises, in sequential order from the conjugate pad: a test region and an optional control region, wherein the test region comprises a spermine carrier protein conjugate comprising spermine conjugated via a second linker to a carrier protein and the optional control region comprises a secondary antibody, wherein the secondary antibody is immobilized on the membrane and the secondary antibody binds to the spermine detection antibody.

[0041] An exemplary testing device is shown in Figure 1. The test device (100) has a sample pad (101), the conjugate pad (102), the membrane (103) comprising test region (103A) and control region (103B), and the absorbent pad (104) mounted on the optional backing card (105). All these components are contiguous and / or overlapping (e.g., by 2 mm) allowing the liquid sample to move through the test strip via capillary action.

[0042] The sample pad comprises a material capable of receiving a liquid sample to be assayed and allowing the liquid sample to migrate to the conjugate pad. The sample can comprise a material selected from the group consisting of fibrous paper; a microporous membrane consisting of cellulose materials, cellulose, a cellulose derivative such as cellulose acetate, nitrocellulose, glass fiber, textiles such as natural cotton and nylon,porous gels, and combinations thereof. In certain embodiments, the sample pad further comprises additional reagents, such as proteins, non-ionic surfactants, and buffer salts. In certain embodiments, the sample pad further comprises one or more additional reagents selected from the group consisting of bovine serum albumin, Tween® 20, Triton™ X-100, glycerol and polyethylene glycol.

[0043] The conjugate pad comprises the spermine-detection antibody conjugate (typically in dry and immobilized form). When the RB comprising the liquid sample flows into the conjugate pad, the spermine-detection antibody conjugate is mobilized, i.e., it is lifted off the conjugate pad material and migrates with the RB into the membrane during which time if spermine is present in the liquid sample a spermine - spermine-detection antibody conjugate complex forms.

[0044] The spermine-detection antibody conjugate comprises the gold nanoparticle conjugated to one more spermine detection antibodies via one or more first linkers.

[0045] The one or more spermine detection antibodies can be the same or different. The one or more spermine detection antibodies are selectively bind to spermine. The type of spermine detection antibody used in the test device and methods described herein is not particularly limited and the present disclosure contemplates all types of spermine detection antibodies that are capable of selectively binding spermine. The spermine detection antibody can be derived from any host species. In certain embodiments, the host species is a rat species, a mouse species, a guinea pig species, a hamster species, a rabbit species, a goat species, a sheep species, a chicken species, a donkey species, a horse species, a cattle species, a dog species, a cat species, a pig species, a monkey species, a Human species, or any other species. In certain embodiments, the host species is a rabbit species.1461 In certain embodiments, the gold nanoparticle is a citrate capped gold nanoparticleconjugated to one more spermine detection antibodies via one or more first linkers, wherein each of the one or more first linkers has a formula: *-S(CH2)m(C=O)NH**-, wherein m is 1-16, * represents a surface of the gold nanoparticle, and N** represents a nitrogen present in each of the one or more spermine-detection antibodies.

[0047] In certain embodiments, m is 1-16, 2-16, 3-16, 4-16, 5-16, 6-16, 7-16, 8-16, 8-14, 10-16, 10-15, 10-14, 10-13, 10-12, 6-14, 7-13, 8-12, or 9-11. In certain embodiments, m is 10. The synthesis of a citrate capped gold nanoparticle conjugated to one more linkers having the formula *-S(CH2)IOC02H, which can be used to prepare the spermine-detection antibody conjugate described herein, is described in US Patent Application No. 15 / 929,495, which is hereby incorporated by reference in its entirety.

[0048] The membrane can comprise any material through which the liquid sample can diffuse by capillary action. For example, the membrane may comprise a material selected from the naturally occurring materials, synthetic materials or naturally occurring materials deformed by synthesis, for example, polysaccharides (e.g., cellulose materials, paper, cellulose derivatives such as cellulose acetate and nitrocellulose); polyether sulfone; polyethylene; nylon; polyvinylidene fluoride; polyester; polypropylene; silica; inorganic materials uniformly dispersed in a porous polymer matrix together with vinyl chloride, vinyl chloride-propylene copolymers and vinyl chloride-vinyl acetate copolymers, for example inactivated alumina, diatomaceous earth, MgSO-i. or other inorganic fine powder material; naturally occurring (e.g., cotton) and synthetic (e.g., nylon or rayon) textiles; porous gels, e.g., silica gel, agarose, dextran and gelatin; polymer films, e.g., polyacrylamide; and the like. In certain embodiments, the membrane comprises nitrocellulose, polyethersulfone, polyethylene, nylon, polyvinylidene fluoride, polyester, polypropylene, or combinations thereof.

[0049] The membrane comprises, in sequential order from the conjugate pad, the test region and the control region.

[0050] The test region comprises the spermine carrier protein conjugate comprising spermine conjugated via the second linker to the carrier protein. The carrier protein aids in immobilizing spermine in the test region. The carrier protein is not particularly limited by the present disclosure. Accordingly, any carrier protein used in the art for immobilizing analytes in LFIA test devices is contemplated by the present disclosure. In certain embodiments, the carrier protein is bovine serum albumin, KLH, thryoglobulin, Concholepas concholepas hemocyanin (CCH), or ovalbumin. In certain embodiments, the carrier protein is bovine serum albumin.

[0051] The second linker is not particularly limited and can be any bifunctional linker known in the art that is capable of covalently conjugating spermine to the carrier protein. In certain embodiments, the second linker is -(N -CH)(CH2)n(CH=Nt)-, wherein n is a whole number selected from 2-5, 2-4, 2-3, or 3-4; N* represents a nitrogen present in the spermine and Ntrepresents a nitrogen present in the carrier protein. In certain embodiments, n is 3.

[0052] As shown in the results of dilution studies in Figure 3, a visual signal is not observed when the test region is prepared by depositing concentrations of the spermine carrier protein conjugate below 0.5 mg / mL. Thus, the test region can be prepared by depositing a solution of the spermine carrier protein conjugate at a concentration of at least 0.5 mg / mL. In certain embodiments, the test region can be prepared by depositing a solution of the spermine carrier protein conjugate at a concentration of 0.5- 1.0 mg / mL. In certain embodiments, the test region can be prepared by depositing a solution of the spermine carrier protein conjugate at a concentration of about 0.75 mg / mL.1531 The control region comprises the secondary antibody immobilized on the surfaceof the control region. The secondary antibody can be a species -specific antiimmunoglobulin antibody specific for the spermine-detection antibody. The secondary antibody can belong to any antibody class (e.g., IgG, IgA, IgD, IgE, and IgM) or isotype. In certain embodiments, the secondary antibody is IgG antibody, such as IgGl, IgG2, IgG3, or IgG4.

[0054] As shown in the results of dilution studies in Figure 6, a visual signal is not observed when the control region is prepared by depositing concentrations of the secondary antibody below 0.05 mg / mL. The control region can be prepared by depositing a solution of the secondary antibody at a concentration of at least 0.05 mg / mL, at least 0.125 mg / mL, at least 0.25 mg / mL, or at least 0.5 mg / mL. In certain embodiments, the control is prepared by depositing a solution of the secondary antibody at a concentration of 0.05 mg / mL to 0.5 mg / mL. In certain embodiments, the control is prepared by depositing a solution of the secondary antibody at a concentration of about 0.25 mg / mL.

[0055] In general, the test region and control region may have any shape, including rectangular shapes, non-rectangular shapes, circular shapes, halfmoon shapes, oval shapes, plus sign shape, minus sign shape, a line, multiple lines, a symbol, a geometric shape, an alpha-numeric shape, or any combination thereof. In certain embodiments, the test region and the control region can be present in the form of a line. Hence, they might herein also be referred to as "test line" and "control line", respectively.

[0056] In certain embodiments, the test device further comprises a backing card, wherein the sample pad, the conjugate pad, the membrane, and the absorbent pad are disposed on a surface of the backing card. The backing card may comprise any material so long as the backing card can support the sample pad, the conjugate pad, the membrane and the absorption pad. In general, it is preferred that the backing card is liquid imperviousso that liquid sample fluids diffusing through the membrane are not leaked. Materials for the backing card may include, but are not limited to glass; polymer materials, e.g., polystyrene, polypropylene, polyester, polybutadiene, polyvinyl chloride, polyamide, polycarbonate, epoxide, methacrylate, and polymelamine.

[0057] The present disclosure also provides a method of detecting spermine in a liquid sample, the method comprising: providing the test device described herein; applying the liquid sample on the sample pad resulting in flow of the liquid sample from the sample pad through the conjugate pad and the membrane to the absorbent pad; detecting a presence or an absence of a visual signal at the test region; and optionally detecting a presence or an absence of a visual signal at the control region, wherein the detection of the presence or the absence of the visual signal at the test region is indicative of spermine in the liquid sample.

[0058] The test device operates in a competitive test assay format, which involves the binding of spermine to the spermine-detection antibody conjugate in the conjugate pad thereby forming a spermine - spermine-detection antibody conjugate complex (if present), which mobilizes, i.e., migrates with the RB. Once the liquid sample in the RB contacts the test region any free spermine-detection antibody conjugate in the liquid sample forms a spermine-detection antibody conjugate - spermine carrier protein conjugate complex, which results in a visual signal at the test region. Once the liquid sample in the RB contacts the control region, the secondary antibody immobilized on the surface of the control region will form a complex with the free spermine-detection antibody conjugate and / or the spermine - spermine-detection antibody conjugate complex thereby resulting in a visual signal at the control region regardless of whether spermine is present in the liquid sample. As illustrated in Figure 1 , when a visual signal is present at the control region but not at the test region, this indicates the presence ofspermine (or a concentration of spermine higher than a threshold concentration) and when a visual signal is present at both the control region and the test region, this indicates the absence of spermine (or a concentration of spermine lower than a threshold concentration).

[0059] In certain embodiments, the liquid sample comprises a urine sample obtained from a human subject and the method further comprises determining based on whether the liquid sample contains spermine above a threshold concentration that the human subject suffers from prostate cancer, has an increased likelihood of suffering from prostate cancer, and / or should undergo additional testing (e.g., digital rectal exam, prostate biopsy, etc) to determine if the human subject suffers from prostate cancer.

[0060] The liquid sample can comprise a biological sample, an environmental sample, a food sample or the like. Exemplary biological samples include bodily fluids, such as urine, whole blood, saliva, sweat, plasma and serum. In certain embodiments, the liquid sample comprises urine.

[0061] The liquid sample can further comprise phosphate buffered saline and optionally bovine serum albumin and a non-ionic-surfactant, such as Tween® 20, Triton™ X- 100, and the like.

[0062] The liquid sample may optionally be diluted prior to addition to the sample pad. In certain embodiments, the liquid sample is prepared by diluting a sample at a volume ratio of 1:1-100 (sample : dilution buffer) with a dilution buffer. Exemplary dilution buffers may include phosphate buffered saline.

[0063] In the examples below, the sample pad and conjugate pad were pretreated with BSA and Tween® 20, to ensure smooth flow and suppress non-specific bindings. The optimal BSA content was set at 1 m / v %. The competitive detection of Spm in the LFIA is facilitated by the AuNPs-Spm-Ab at the conjugate pad and the BSA-Spm conjugateat the test line. The AuNPs-Spm-Ab firstly binds to the Spm in the RB, then the unreacted AuNPs-Spm-Ab bind to the BSA-Spm conjugate at the test line. Finally, the flow passes through the control line with IgG and absorbed by the absorbent pad. The positive result corresponds to the appearance of two lines, indicates the insufficient Spm concentration in the liquid sample and risk of PC.

[0064] Synthesis, modification and conjugation of gold nanoparticles

[0065] The as-prepared Cit-AuNPs presented a size of around 13 nm with spherical morphology in the TEM image (Figure 2(a) and inset). The ligand exchange from citrate to carboxylic acid was achieved by the thiol-gold chemisorption of MUA. Figure 2(b) indicates the successful ligand exchange by monitoring the shift in the absorption maxima. There is no broadening of curve, suggesting the MUA exchange did not cause aggregation to AuNPs. The Spm-Ab was conjugated to the carboxylic acid group by one-pot EDC / NHS coupling in borate buffer, targeting the amine groups on the molecule. After that, the as-prepared AuNPs-Spm-Ab was dispersed in PB with sucrose and Tween® 20 to prevent precipitation. To gain more insight on the actual size of the AuNPs-Spm-Ab in the buffer, the DLS sizes of the AuNPs at each modification step were shown in Figure 2(c). The increases in size of AuNPs is consistent with the conjugation steps, there is also no significant broadening of size distribution. Moreover, the gel electrophoresis image in Figure 2(d) provides more evidence for the successful conjugation of Spm-Ab on AuNPs. The first two lanes correspond to Cit-AuNPs and MUA- AuNPs while the lanes labelled with AuNP- Anti consist of Spm-Ab. It is obvious that the AuNPs-Spm-Ab migrates a shorter distance compared to the Cit-AuNPs and MUA-AuNPs. This was attributed to the increased loading of Spm-Ab.

[0066] Optimization of control and test regions1671 The concentrations of the BSA-spm and IgG at the test and control lines are crucialfor a visible signal. Insufficient concentrations can result in a slow response of the immobilized receptors towards the flow and hence no observable signals.

[0068] IgG does not give rise to a clear signal until a concentration of > 0.05 mg / mL and displays a strong interaction with the AuNPs-Spm-Ab at 0.25 mg / mL (Fig. 6). Therefore, this concentration was maintained throughout the experiments.

[0069] On the hand, no signal was observed until the concentration of BS A-Spm reached 0.5 mg / mL. 1 mg / mL BSA-Spm provided a clear signal at the test line, therefore this concentration was chosen for the subsequent fabrications and testing of the LFIA.

[0070] Detection of spermine using the lateral flow immunoassay

[0071] Spermine was spiked to the RB at different concentrations (2, 1, 0.2, 0.1 and ppm) to test the cut off concentration for screening normal and potential PC patients. The test was performed for 10 min and the images of the strips were shown in Figure 3. At 1 and 2 ppm, the LFIA reported a single red line at the control line. This observation was attributed to the reacted AuNPs-Spm-ab with the spiked Spm in the RB. As a result, there was no binding at the test line. Two lines were observed when the Spm concentration decreased to 0.2 ppm. The appearance of the faint red line at the test line was due to the binding of unreacted AuNPs-Spm-ab with the BSA-Spm at the test line, this also indicated the insufficient amount of Spm in the liquid sample. The intensities of the test line were further enhanced at 0.1 and 0.02 ppm of Spm, because of the amount of unreacted AuNPs-Spm-Ab increased.

[0072] Specificity of the lateral flow immunoassay

[0073] The LFIA was tested with different amines for investigating its specificity. Figure 5 shows the results of the specificity test with putrescine (PUT) and 1 ,6- di aminohexane. PUT is the similar biogenic amine with Spm in the biogenic amine family25-27while 1,6-diaminohexane has similar structure as Spm. The concentrations of the amines weremaintained at 0.2 ppm for comparison with the Spm detection results. The LFIA both indicated insufficient amount of Spm in the liquid sample, which indicated the good selectivity of the LFIA.

[0074] Conclusion

[0075] A competitive LFIA detection for Spm was developed using AuNPs-Spm-Ab as the bio-probe and BSA-Spm as the carrier protein-conjugate. The AuNPs-Spm-Ab, control and test line were optimized to provide a cut off concentration at 0.2 ppm, for rapid screening of potential PC patients. Moreover, the LFIA were tested with spiked Spm liquid samples at different concentrations. The positive results indicated the low Spm concentration and implied the risk of PC. The sensor was able to determine the normal Spm concentration of the liquid samples in around 10 min with high specificity. The developed LFIA for Spm is expected to be useful for future clinical PC screening applications.

[0076] Examples

[0077] Materials

[0078] Gold (III) chloride trihydrate (HAuCL), trisodium citrate (Na3-Cit), 11- mercaptoundecanoic acid (MUA), sucrose, Tween® 20 (polyoxyethylene (20) sorbitan monolaurate), borate buffer powder, and hydrochloric acid were purchased from Sigma- Aldrich. l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC-HC1), sulfo-NHS (N-hydroxy sulfosuccinimide) (S-NHS), BSA powder and phosphate buffer (PB, pH 7.4) powder were obtained from Thermofisher. Antispermine rabbit polyclonal IgG (Spm-Ab) and goat anti-rabbit polyclonal IgG (HRP) were purchased from Abeam. The BSA-Spm conjugate (spermine conjugated to BSA via a glutaraldehyde linker) was purchased from Creative Diagnostics. The purities of the chemicals are analytical grade and used without purifications. All dilutions andliquid sample preparations were done by using ultrapure water from MilliQ water purification system. For the LFIA device components, the backing card was purchased from Kenosha Tapes, while glass fiber liquid sample and conjugate pad were obtained from Millipore. The absorbent pad was purchased from Whatman, and NCM, Hi-Flow Plus, HF180, were purchased from Merck.

[0079] Equipment

[0080] Transmission electron microscope (JEM-2100F, Jeol, Japan) was used to examine the morphology and size of the gold nanoparticles. The UV-vis absorption spectra were recorded by using an Agilent 8453 diode array spectrophotometer (Agilent Technologies, USA) and the hydrodynamic size of the AuNPs at each modification stage was monitored by the Zetasizer (Malvern, UK). A lateral flow printer (Agismart RP-2000, Rega Biotechnology Inc) was used to dispense the test and control line on the NC-M. The lateral flow strip cutter (LFST0007, Lateral Flow Strip Cutter, China) was used to cut the LFIAs.

[0081] Example 1 - Preparation of citrate-stabilized AuNPs (Cit- AuNPs)

[0082] The Cit- AuNPs were synthesized according to our previous work.22, 24Briefly, 1 mL of 2 wt % Nas-Cit solution was added into 25 mL MilliQ in a 125 mL conical flask under magnetic stirring. After that, 1.25 mL of 10 mM HAuCU solution is swiftly pipetted into the boiled citrate solution under vigorous stirring. The colorless mixture gradually changed to black, purple and red color, which was attributed to AuNPs formation. The citrate-AuNPs colloidal solution was cooled to room temperature and stored at 4 °C for further modifications.

[0083] Example 2 - Preparation of AuNPs-Spm-Ah

[0084] 200 uL of 25 mM MUA solution was added to the Cit-AuNPs colloidal under stirring at room temperature for 24 h. The MUA- AuNPs colloidal is kept at 4 °C untilfurther use. Then, Spm-Ab was conjugated to the MUA-AuNPs via carbodiimide chemistry. Briefly, 2.5 pL of EDC-HC1 (50 mM) and S-NHS (50 mM) were added to 200 uL of MUA-AuNPs in 10 mM borate buffer (pH 8) under shaking. Then, 5 pL of 100-fold diluted Spm-Ab was added to the mixture and react for 2 h. The resultant Au- Spm-Ab was purified by centrifugation and dispersed in PB (5 % sucrose and 0.5 % Tween® 20).

[0085] Example 3 - Preparation of the LFIA

[0086] The liquid sample and conjugate pad were pretreated before assembling onto the backing card. The sample pad was soaked with 10 mM PB buffer consisting of 1 % BSA and 0.5 % Tween® 20 for 1 h while the conjugate pad was treated with 10 mM PB with 5 % sucrose and 0.5 % Tween® 20 for 1 h. The pretreated pads were dried at 37 °C for 4 h. On the other hand, InM AuNPs-Spm-Ab was sprayed on the conjugate pad and dried overnight at 37 °C. The dispensing rate was set at 0.100 pL / mm for the fabrication of the strip. The BSA-Spm conjugate (1 mg / mL) and goat anti-rabbit IgG (0.25 mg / mL) were dispensed onto nitrocellulose membrane as the test and control regions, respectively. The components were assembled onto the backing card with an overlapping of 1 mm and dried overnight at 37 °C. After that, the LFIA were cut into 3 mm wide and stored in dry box.

[0087] Example 4 - Lateral flow assay with spiked Spm liquid sample

[0088] Spm solution was spiked at 2, 1, 0.5, 0.2 and 0.1 ppm into the RB, which contain 10 mM PB, 1 % BSA and 0.5 % Tween® 20. The total volume added to the LFIA was 60 pL and the assay was performed for 10 min for completion.

[0089] Example 5 - Clinical urine sample testing and diagnosis of prostate cancer

[0090] A total of 48 clinical urine samples were obtained from male patients, 15 were diagnosed to have prostate cancer (PCa) and the remaining 33 samples were evaluatedas having no evidence of malignancy (NEM). The Spm levels in these clinical samples were quantified by liquid chromatography-tandem mass spectrometry (LC-MS / MS). The range of Spm levels from PCa is 18.64 - 2287.08 ppb, with median 156.19 ppb, whereas that from NEM is 54.20 - 2790.33 ppb, with median 366.11 ppb.

[0091] Samples for LFIA were prepared by mixing 25 uL of clinical urine sample well with 25 uL running buffer (10 mM phosphate buffer (PB), 1% BSA, 0.5% Tween® 20, pH 7.4). The LFIA was utilized as a screening tool for prostate cancer through the rapid sensing of Spm. The samples were applied onto sample pad and 15 min was taken to ensure stable visualization of control region and / or test region. The results are shown in Fig. 7 and the kit has 86.7% sensitivity and 36.3% specificity.References1. H. Sung, J. Ferlay, R. L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal and F. Bray, CA Cancer J Clin, 2021, 71, 209-249.2. M. B. Culp, I. Soerjomataram, J. A. Efstathiou, F. Bray and A. Jemal, Eur Urol, 2020, 77, 38-52.3. Fritz H. Schro ’der, P. v. der, P. B. Maas, Arto Boeken Kruger, Robert, Hoedemaeker, John Rietbergen and R. Kranse, Journal of the National Cancer Institute, 1998, 90, 1817-1823.4. L. Naji, H. Randhawa, Z. Sohani, B. Dennis, D. Lautenbach, O. Kavanagh, M. Bawor, L. Banfield and J. Profetto, Ann Fam Med, 2018, 16, 149-154.5. M. J. Connor, M. A. Gorin, D. Eldred-Evans, E. J. Bass, A. Desai, T. Dudderidge, M. Winkler and H. U. Ahmed, Nat Rev Urol, 2023, DOI: doi.org / 10.1038 / s41585-022-00684-0.6. S. Loeb, A. Vellekoop, H. U. Ahmed, J. Catto, M. Emberton, R. Nam, D. J.Rosario, V. Scattoni and Y. Lotan, Eur Urol, 2013, 64, 876-892. S. W. D. Merriel, L. Pocock, E. Gilbert, S. Creavin, F. M. Walter, A. Spencer and W. Hamilton, BMC Med, 2022, 20, 54. S. S. Dinges, A. Hohm, L. A. Vandergrift, J. Nowak, P. Habbel, I. A. Kaltashov and L. L. Cheng, Nat Rev Urol, 2019, 16, 339-362. H. Lemos, L. Huang, G. C. Prendergast and A. L. Mellor, Nat Rev Cancer, 2019, 19, 162-175. E. R. Still and M. O. Yuneva, Br J Cancer, 2017, 116, 1375-1381. C. E. Condrat, D. C. Thompson, M. G. Barbu, O. L. Bugnar, A. Boboc, D.Cretoiu, N. Suciu, S. M. Cretoiu and S. C. Voinea, Cells, 2020, 9. J. Wang, J. Chen and S. Sen, J Cell Physiol, 2016, 231, 25-30. Y. Y. Broza, X. Zhou, M. Yuan, D. Qu, Y. Zheng, R. Vishinkin, M. Khatib, W.Wu and H. Haick, Chem Rev, 2019, 119, 11761-11817. A. A. Bhosle, M. Baneqee, S. D. Hiremath, D. S. Sisodiya, V. G. Naik, N. Barooah, A. C. Bhasikuttan, A. Chattopadhyay and A. Chatterjee, J Mater Chem B, 2022, 10, 8258-8273. J. R. Bhamore, Z. V. P. Murthy and S. K. Kailasa, Journal of Molecular Liquids, 2019, 280, 18-24. S. Luhar, R. Ghosh, P. B. Chatterjee and D. N. Srivastava, Biosensors and Bioelectronics: X, 2022, 12, 100219. B. G. Andryukov, AIMS Microbiol, 2020, 6, 280-304. T. Nicol, C. Lefeuvre, O. Serri, A. Pi vert, F. Joubaud, V. Dubee, A. Kouatchet, A. Ducancelle, E Lunel-Fabiani and H. Le Guillou-Guillemette, J Clin Virol,2020, 129, 104511. T. Wen, C. Huang, F. J. Shi, X. Y. Zeng, T. Lu, S. N. Ding and Y. J. Jiao, Analyst, 2020, 145, 5345-5352. B. Keskin, A. Uzer and R. Apak, ACS Omega, 2022, 7, 28065-28075. A. Sen, C. Sester, H. Poulsen and J. M. Hodgkiss, ACS Appl Mater Interfaces, 2022, 14, 32813-32822. T. H. Tsoi, Y. J. Gu, W. S. Lo, W. T. Wong, W. T. Wong, C. F. Ng, C. S. Lee and K. L. Wong, Chempluschem, 2017, 82, 802-809. P. K.-F. Chiu, Y.-H. Fung, J. Y.-C. Teoh, C.-H. Chan, K.-L. Lo, K.-M. Li, R. T.- H. Tse, C.-H. Leung, Y.-P. Wong, M. J. Roobol, K.-L. Wong and C.-F. Ng, Prostate Cancer and Prostatic Diseases, 2021, 24, 542-548. M. K. Tsang, Y. T. Wong, T. H. Tsoi, W. T. Wong and J. Hao, Adv Healthc Mater, 2019, 8, 1900575. F. Kong, Y. Mu, X. Zhang, Q. Lu, Z. Yang, J. Yao and L. Zhao, RSCAdv, 2022, 12, 26630-26638. B. Del Rio, B. Redruello, D. M. Linares, V. Ladero, P. Ruas-Madiedo, M. Fernandez, M. C. Martin and M. A. Alvarez, Sci Rep, 2019, 9, 120. T. Leelasree and H. Aggarwal, Journal of Materials Chemistry C, 2022, 10, 2121-2127.

Claims

What is claimed is:

1. A test device for detecting spermine in a liquid sample, the test device comprising, in sequential order: a sample pad, a conjugate pad, a membrane, and an absorbent pad, wherein: the conjugate pad comprises a spermine-detection antibody conjugate comprising a gold nanoparticle conjugated to one more spermine detection antibodies via one or more first linkers, wherein the one or more spermine detection antibodies selectively bind to spermine and the spermine-detection antibody conjugate is mobilizable; the membrane comprises, in sequential order from the conjugate pad: a test region and a control region, wherein the test region comprises a spermine carrier protein conjugate comprising spermine conjugated via a second linker to a carrier protein and the control region comprises a secondary antibody, wherein the secondary antibody is immobilized on the membrane and the secondary antibody binds to the spermine detection antibody.

2. The test device of claim 1, wherein the gold nanoparticle is a citrate capped gold nanoparticle.

3. The test device of claim 1, wherein each of the one or more first linkers has a formula: *-S(CH2)m(C=0)NH**-, wherein m is 1-16, * represents a surface of the gold nanoparticle, and N** represents a nitrogen present in the one or more sperminedetection antibodies.

4. The test device of claim 3, wherein m is 6-12.

5. The test device of claim 1, wherein the carrier protein comprises bovine serum albumin, human serum albumin, keyhole limpet hemocyanin, Concholepas concholepas hemocyanin or immunoglobulin Fc domain.

6. The test device of claim 1 , wherein the secondary antibody is an immunoglobulin G (IgG) antibody.

7. The test device of claim 1 , wherein the sample pad further comprises bovine serum albumin and a non-ionic surfactant and the conjugate pad further comprises a non-ionic surfactant.

8. The test device of claim 1, wherein the second linker is -(N*=CH)(CH2)n(CH=Nt)-, wherein n is a whole number selected from 2-6; N* represents a nitrogen present in the spermine and N " represents a nitrogen present in the carrier protein.

9. The test device of claim 1, wherein the gold nanoparticle is a citrate capped gold nanoparticle, the carrier protein is bovine serum albumin, the second linker is - (Nt=CH)(CH2)n(CH=N#)-, wherein n is a whole number selected from 2-5; N* represents a nitrogen present in the spermine and N#represents a nitrogen present in the carrier protein, each of the one or more first linkers has a formula: *-S(CH2)m(C=0)NH**-, wherein m is 8-12, * represents a surface of the gold nanoparticle, and N** represents a nitrogen present in each of the one or more spermine-detection antibodies.

10. The test device of claim 9, wherein the test region is prepared by depositing a solution comprising the spermine-carrier protein at a concentration of 0.5-1.0 mg / mL.

11. The test device of claim 9, wherein the control region is prepared by depositing a solution comprising an immunoglobulin G (IgG) antibody at a concentration of at least 0.05 mg / mL.

12. The test device of claim 9, wherein the test region is prepared by depositing a solution comprising the spermine-carrier protein at a concentration of 0.5-1.0 mg / mL; and the control region is prepared by depositing a solution comprising an immunoglobulin G (IgG) antibody at a concentration of at least 0.05 mg / mL.

13. The test device of claim 12, wherein m is 10 and n is 3.

14. A method of detecting spermine in a liquid sample, the method comprising: providing the test device of claim 1 ; applying the liquid sample on the sample pad resulting in flow of the liquid sample from the sample pad through the conjugate pad and the membrane to the absorbent pad; detecting a presence or an absence of a visual signal at the test region; and optionally detecting a presence or an absence of a visual signal at the control region, wherein the detection of the presence or the absence of the visual signal at the test region is indicative of spermine in the liquid sample.

15. The method of claim 14, wherein the detection of the presence or the absence of the visual signal at the test region is indicative of spermine above a threshold concentration in the liquid sample.

16. The method of claim 14, wherein the liquid sample comprises a urine sample obtained from a subject.

17. The method of claim 14, wherein the liquid sample further comprises phosphate buffered saline.

18. The method of claim 17, wherein the liquid sample further comprises bovine serum albumin and a non-ionic surfactant.

19. The method of claim 17, wherein the sample pad further comprises bovine serum albumin and a non-ionic surfactant and the conjugate pad further comprises a non-ionic surfactant.

20. The method of claim 15, wherein the liquid sample comprises a urine sample obtained from a human subject and the method further comprises determining based on whether the sample contains spermine above the threshold concentration that the human subject suffers from prostate cancer.

Citation Information

Patent Citations

  • Detection method and detection device for polyamine

    JP2022061489A

  • Methods and apparatus for detecting compounds in liquids

    US20170269108A1

  • Urinary Polyamines as Prostate Cancer Detection Biomarkers

    US20180252652A1

  • Direct Colorimetric Detection of Spermine using Gold Nanoparticles

    US20200355691A1

  • Lateral flow immunoassay strip device

    US20210033605A1